Summary of Product Characteristics Updated 16-Sep-2025 | Sigma Pharmaceuticals PLC (Special Concept Development / RxFarma)
Fluoritop® LF 2800 ppm Fluoride Toothpaste
1 g of toothpaste contains contains 2.8 mg fluoride (as sodium fluoride), corresponding to 2800 ppm fluoride, sodium fluoride 0.619% w/w.
Excipients with known effect:
Sorbitol and Sodium benzoate
For full list of excipients, see section 6.1
Toothpaste
A white homogenous paste.
For dental use.
Fluoritop 2800 ppm toothpaste is indicated for the prevention and treatment of dental caries (coronal and root) in adolescents and children over 10 years.
Posology:
Paediatric population:
Fluoritop 2800 ppm Toothpaste is contraindicated in children aged less than 10 years, see section 4.3.
Adolescents and children over 10 years old:
Use daily instead of the normal toothpaste.
The usual dosage is to apply a 1 cm line of paste across the head of a toothbrush and brush the teeth thoroughly for one minute morning and evening. Spit out after use; for best results do not drink or rinse for 30 minutes.
Not to be swallowed.
Method of Administration:
For dental use
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Individuals with known sensitivities should consult their dentist before using
Not to be used in children under 10 years old.
Not to be swallowed.
An increased number of potential fluoride sources may lead to fluorosis. In order to prevent the accumulation of fluoride, the total fluoride intake must be assessed before this fluoride toothpaste is used.
When carrying out overall calculations of the recommended fluoride ion intake, which is 0.05 mg/ Kg body weight per day from all sources, not exceeding 1 mg per day, allowance must be made for possible ingestion of toothpaste (each 75 ml tube of Fluoride 2800 ppm Toothpaste contains 280 mg of fluoride ions).
Other Excipients:
This product contains Sorbitol. Patients with rare hereditary problems of fructose intolerance should not take this medicine.
This product also contains Sodium Benzoate. Sodium Benzoate is a mild irritant to the skin, eyes and mucous membrane.
No interaction studies have been performed.
Pregnancy
Epidemiological studies in humans indicate that fluoride has no adverse effects in pregnancy or on the health of the foetus or newborn child.
No effects during pregnancy are anticipated, since systemic exposure to Sodium Fluoride is negligible. Fluoritop Toothpaste can be used during pregnancy.
Breast-feeding
No effects on the breastfed newborn/infant are anticipated since the systemic exposure of the breast-feeding woman to Sodium Fluoride is negligible.
Fluoritop Toothpaste can be used during breast-feeding.
Fertility
There is no adequate data on the use of Fluoritop 2800 ppm Toothpaste and effects on fertility. Studies in animals have shown reproductive toxicity of sodium fluoride only when administered at very high levels (see section 5.3).
Not applicable
Immune system disorders:
Rare (> 1 / 10,000, < 1 / 1,000): hypersensitivity reactions.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow card Scheme at www.mhra.gov.uk/yellowcard
Acute Intoxication:
In very high doses, fluoride can have an acute toxic effect. Doses of several milligrams of fluoride per kg of body weight may cause nausea, vomiting, and diarrhoea. Tetany and convulsion can occur, as well as cardiovascular disorders.
Increased risk of bone fracture and skeletal fluorosis (stiffness of joints and skeletal deformities) will only be observed in cases of very high chronic intake of fluoride.
Treatment:
Treatment and management should be symptomatic.
In case of mild gastrointestinal overdose symptoms a small glass of milk to drink should be given to bind fluoride ion.
It should be noted that gut decontamination is contraindicated. Charcoal is of no benefit.
Chronic Intoxication (Fluorosis):
The dental enamel will take on a stained or speckled appearance once a fluoride dosage in excess of 1.5 mg per day is absorbed daily over several months or years, depending on the extent of overdose. This will be accompanied by increased enamel fragility in severe forms. Bone fluorosis (osteosclerosis) will only be seen where there is high chronic absorption of fluoride (over 8 mg daily).
Pharmaco-therapeutic group: caries prophylactic agents
ATC-code: A01AA01
This product is a tooth paste in which the active ingredient is sodium fluoride present at a level of 0.619 % w/w, which corresponds to 280 mg fluoride per 100 g toothpaste.
Sodium fluoride applied topically after tooth eruption reduces caries by inhibiting demineralisation and promoting remineralisation of the tooth surface. It is effective on both enamel and exposed dentine.
Fluoritop toothpaste has a local, topical action on the teeth and so the route taken within the body does not apply. This product is not intended to be swallowed and therefore only minimal systemic exposure is expected. However, the following information has been included in case any toothpaste is accidentally ingested during treatment.
Absorption
Ingested fluoride is converted to hydrofluoric acid. Peal concentrations are achieved within 30 – 60 minutes.
Distribution
The volume of distribution is 1 L / Kg. Fluoride ions are distributed to teeth and bones, and are not bound to plasma proteins.
Biotransformation
Ingested fluoride is converted to hydrofluoric acid.
Elimination
The terminal half life is in the range 2 – 9 hours. Fluoride ions are excreted mainly in urine, but small amounts may also be excreted in faeces and sweat. It is not known in which form.
Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential and toxicity to reproduction and development.
After oral administration of sodium fluoride to mice, rats and rabbits, reproductive and foeto–toxic effects were observed only at high dose levels.
Glycerol E422
Sorbitol, liquid (non-crystallising) E420
Carmellose Sodium
Sodium Saccharine
Sodium Benzoate E211
Macrogols 600
Dental type silicas
Titanium Dioxide E171
Sodium laurilsulfate
Flavour mint SC
Purified water
None known
3 years unopened
6 months after opening
This product requires no special storage conditions.
75 ml polypropylene / aluminium / polyethylene laminated tube with a polypropylene flip-top cap.
Pack sizes: 1 x 75ml tube
Any unused medicinal product or waste material should be disposed of in accordance with local requirements.
Special Concept Development (UK) Limited T/A Rx Farma.
Colonial Way,
Watford WD24 4YR,
United Kingdom.
PL 36722/0076
22/01/2019
25/07/2025
HD House, Imperial Way, North Watford, Hertfordshire, WD24 4LQ, UK
+44 (0)800 358 0163
+44 (0)800 358 0163
http://www.sigmaplc.com/our-product-offerings/rxfa
+44 (0)800 358 0163